AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04052009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-effector based gait training
Description: Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
Study NCT04052009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined training (conventional and end-effector-based)
Description: Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
Study NCT02951780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3185643
Description: Administered SC
Study NCT02951780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rGlucagon
Description: Administered SC
Study NCT00492453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
Study NCT01402921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V0322 BC
Description: * Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment
Study NCT01402921 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: V0322 BC
Description: * Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment
Study NCT02359903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (BCD-055)
Description: infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
Study NCT02359903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab (Remicade)
Study NCT01855386 — intervention group
Intervention type: OTHER
Intervention: Subjects with Gestational Diabetes
Description: Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
Study NCT01855386 — intervention group
Intervention type: OTHER
Intervention: Controls without Gestational Diabetes
Description: Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
Study NCT03306550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolate injection
Description: The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
Study NCT03306550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salvianolate injection
Description: The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
Study NCT03306550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Tablet
Description: Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
Study NCT03306550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Tablet
Description: Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
Study NCT01769924 — intervention group
Intervention type: OTHER
Intervention: Nephrectomy
Description: Nephrectomy for the purposes of living kidney donation
Study NCT02639689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WALKAIDE
Description: A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device.
Study NCT01663792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seaweed
Description: Ten 500-mg capsules to be taken orally each day for 1 month
Study NCT01663792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ten 500-mg capsules to be taken orally each day for 1 month
Study NCT01663792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo2
Description: Ten 500-mg capsules to be taken orally each day for 1 month
Study NCT03508050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clamping the Double Lumen Tube
Description: Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
Study NCT01465009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
Study NCT01465009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
Study NCT01465009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
Study NCT01246882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented activity feedback
Description: Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
Study NCT02135042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo clinical observation
Study NCT02135042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT04208269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Information Technology system
Description: Accessed by adolescent and provider only
Study NCT02335515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soctec
Description: Gastroretentive Drug Delivery System
Study NCT02477852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: preoperative treatment of spinal tuberculosis with Isoniazid
Study NCT02477852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: preoperative treatment of spinal tuberculosis with Rifampicin
Study NCT02477852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: preoperative treatment of spinal tuberculosis with Ethambutol
Study NCT02135042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02135042 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02135042 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02135042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02135042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02135042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02135042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02135042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01900834 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: The participants will not receive any treatment
Study NCT00654316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: intradermal injection of 0.1ml BCG over the deltoid muscle
Study NCT01733095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
Study NCT00044863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erbitux (Cetuximab)
Description: 400 mg/m2 initial dose, 250 mg/m2 weekly
Study NCT03629392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High met/cys diet
Description: Dietary intervention with high contents of methionine and cysteine
Study NCT01938963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborations in Health (COACH)
Description: Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
Study NCT02586233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
Study NCT02586233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
Study NCT02673892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Oriented Discharge Summary
Description: The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
Study NCT03695640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Addition of magnesium sulfate as an adjuvant to levobupivacaine
Study NCT03695640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous femoral nerve block
Description: continuous nerve block with levobupivacaine for treatment postoperative pain
Study NCT03695640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous femoral nerve block
Description: continuous nerve block with levobupivacaine for treatment postoperative pain
Study NCT02713763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg/day
Study NCT02919124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echoclip
Description: An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
Study NCT03007485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Pulmonary Rehabilitation
Description: Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
Study NCT03773926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-feedback therapy
Description: The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
Study NCT01471704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189 50 mg
Description: Study Day 0: Single 50 mg dose of INX-08189 in the morning
Study NCT01471704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 240 mg verapamil HCL ER
Description: Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
Study NCT01471704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg dose of INX-08189 and 240 mg verapamil HCL ER
Description: Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
Study NCT00621452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study NCT00621452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00621452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously
Study NCT00621452 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00621452 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene rearrangement analysis
Description: Correlative studies
Study NCT00621452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node biopsy
Description: Optional correlative studies
Study NCT00621452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: genetically engineered lymphocyte therapy
Description: Receive genetically modified T cells
Study NCT00621452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Optional correlative studies
Study NCT00621452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00621452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00621452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT02634099 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: blood measurement
Description: Hemoglobin measurement
Study NCT02634099 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pulse co-oxymeter (SpHb)
Description: non invasive method of hemoglobin measurement
Study NCT02634099 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hemoCue
Description: non invasive method of hemoglobin measurement
Study NCT03183830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich Beetroot Juice
Description: The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study NCT02477852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: preoperative treatment of spinal tuberculosis with Pyrazinamide
Study NCT00289835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent
Description: Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
Study NCT00289835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Paclitaxel eluting stent
Description: Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
Study NCT01204346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBT
Description: The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
Study NCT01204346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: less intensive and structured psychotherapeutic program
Study NCT03584659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes
Description: Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
Study NCT02763033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bob's Red Mill®
Description: Standard bone marrow transplant (BMT) diet + potato-based starch
Study NCT03183830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-deplete Beetroot Juice
Description: See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study NCT02763033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch Placebo
Description: Standard bone marrow transplant (BMT) diet + corn-based starch
Study NCT02763033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Starch Placebo
Description: Standard bone marrow transplant (BMT) diet + corn-based starch
Study NCT04508920 — intervention group
Intervention type: OTHER
Intervention: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
Description: Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
Study NCT01715636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
Study NCT00483093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
Study NCT01129934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine-Promethazine
Description: administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
Study NCT01129934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Administration of intravenous morphine 0.1 mg/kg
Study NCT00483093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
Study NCT01246882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed-only feedback
Description: Feedback about walking speed will be provided 3 times per week.
Study NCT01077063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Description: surgical drainage of malignant ascites
Study NCT01077063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleurx catheter
Description: take home catheter drainage system that the subject uses himself/herself as needed.
Study NCT03858426 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00419549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl - trinitrate
Description: Transdermal Patch once only
Study NCT00419549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valdecoxib
Description: Single parenteral administration
Study NCT00619359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fosaprepitant dimeglumine
Description: single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.